Please try another search
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Name | Age | Since | Title |
---|---|---|---|
Jill M. Jene | 49 | 2022 | Independent Director |
Mahesh V. Patel | 65 | 1997 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO |
Rex P. Hjelm | - | - | Member of Scientific Advisory Board |
William N. Charman | 63 | - | Member of Scientific Advisory Board |
Richard Dana Ono | 70 | 2014 | Independent Director |
Alan F. Hofmann | - | - | Member of Scientific Advisory Board |
George Zografi | - | - | Member of Scientific Advisory Board |
Leslie Z. Benet | 85 | - | Member of Scientific Advisory Board |
Tsuneji Nagai | - | - | Member of Scientific Advisory Board |
John W. Higuchi | 55 | 2003 | Director |
Bradley D. Anderson | - | - | Member of Scientific Advisory Board |
Ronald T. Borchardt | - | - | Member of Scientific Advisory Board |
Norman Ho | - | - | Member of Scientific Advisory Board |
Jeffrey Arvin Fink | 65 | 2014 | Independent Director |
Spyridon Papapetropoulos | 51 | 2022 | Lead Independent Director & Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review